Shree Ganesh Remedies Ltd

Shree Ganesh Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 20 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Shree Ganesh Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a recent day decline of 4.81%, the stock’s technical indicators present a complex picture, with mixed signals across weekly and monthly timeframes. This article analyses the evolving price momentum, key technical indicators such as MACD, RSI, moving averages, and their implications for investors.

Shree Ganesh Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 20 May 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 01 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

With a decisive break above Rs 665 on 29 Jun 2026, Shree Ganesh Remedies Ltd has reached a fresh 52-week high, marking a notable milestone in its price momentum. This advance comes amid a backdrop of strong technical signals and a market environment where the broader indices show mixed trends.

With a decisive surge to Rs 660 on 26 Jun 2026, Shree Ganesh Remedies Ltd has reached a fresh 52-week high, marking a notable milestone in its price momentum. This advance comes amid a backdrop of broad technical alignment and outperformance relative to the Sensex over the past year.

With a decisive surge to Rs 648.5 on 25 Jun 2026, Shree Ganesh Remedies Ltd has reached a fresh 52-week high, marking a notable milestone in its price momentum. This rally is underpinned by a confluence of bullish technical indicators and sustained outperformance against its sector and the broader market.

Shree Ganesh Remedies Ltd has witnessed a notable shift in its technical momentum, with key indicators signalling a transition from mildly bullish to bullish territory. The stock’s recent price surge, coupled with upgraded technical grades and improved momentum metrics, suggests growing investor confidence in this micro-cap pharmaceutical player.

Shree Ganesh Remedies Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a stabilisation in its financial performance and a shift towards a more positive technical outlook. The upgrade, effective from 20 May 2026, is driven by improvements across four key parameters: quality, valuation, financial trend, and technical indicators, signalling cautious optimism for investors in this micro-cap pharmaceutical player.

Shree Ganesh Remedies Ltd has witnessed a notable shift in its technical momentum, moving from a mildly bearish stance to a mildly bullish outlook. Despite a slight dip in the stock price on 21 May 2026, the evolving technical indicators suggest a nuanced market sentiment for this micro-cap pharmaceutical player, warranting close attention from investors and analysts alike.

The 50-day moving average has crossed above the 200-day moving average for Shree Ganesh Remedies Ltd, signalling a golden cross on 20 May 2026. Yet, the stock declined 0.66% on the same day, while monthly momentum indicators remain bearish. This juxtaposition of signals invites a closer examination of the technical and fundamental context behind the crossover.

Shree Ganesh Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported its March 2026 quarter results reflecting a nuanced financial performance. While net sales and operating profits reached record highs, key profitability metrics and financial ratios indicate emerging challenges, signalling a shift from a previously flat to a negative financial trend.

Shree Ganesh Remedies Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Shree Ganesh Remedies Ltd., a Gujarat-based manufacturer of pharmaceutical intermediates and fine chemicals, reported a strong sequential recovery in its fourth-quarter results for FY26, with net profit surging 102.91% quarter-on-quarter to ₹6.27 crores. However, the year-on-year comparison reveals persistent challenges, as profits declined 4.86% compared to Q4 FY25's ₹6.59 crores, highlighting margin compression despite revenue growth. The micro-cap company, with a market capitalisation of ₹691.00 crores, saw its shares rally 7.93% to ₹537.90 following the results announcement, though the stock remains 32.25% below its 52-week high of ₹794.00.

Shree Ganesh Remedies Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Jan 2026, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 04 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall outlook.

Shree Ganesh Remedies Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 12 January 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 23 April 2026, providing investors with the latest comprehensive analysis.